Purification of IDPs |
Purification under denaturing conditions |
• In principle, compatible with all IDP/IDRs |
• Denaturant must be removed |
27, 28 and 172
|
• Refolding required for constructs that contain both folded and IDR domains |
Purification at extreme pH |
• Straightforward recovery of target protein |
• Applicable to only a small subset of proteins |
18 and 22–26
|
Purification at extreme temperature |
• Straightforward recovery of target protein |
• Applicable to only a small subset of proteins |
26
|
Labeling with spectroscopic or imaging probes |
Maleimide or iodoacetamide-based probes |
• Site-specific at cysteine residues |
• Not applicable in cells |
36–41
|
• Compatible with isotopic labeling for NMR |
• Potential labeling at multiple sites |
• Probes may perturb IDP function and LLPS |
N-Hydroxysuccininimide ester-based chemistry |
• Site-specific at lysine residues |
• Not applicable in cells |
42
|
• Compatible with isotopic labeling for NMR |
• Potential labeling at multiple sites |
• Probes may perturb IDP function and LLPS |
Fusion protein-based approaches |
• Genetically encoded |
• Large fusion proteins may perturb IDP function and LLPS |
See ref. 41 and 183 for comparison of the effects on LLPS of small molecule labeling vs. fusion protein labeling |
• Applicable in cells |
Bioorthogonal chemical approaches and amber suppression |
• Genetically encoded |
• UAA incorporation may be inefficient and lead to low protein yields |
56, 61–67, 70, 184 and 185
|
• Applicable in cells |
• Probes may perturb IDP function and LLPS |
• Site-specific labeling |
• May be compatible with isotopic labeling for NMR |
Native chemical ligation and expressed protein ligation |
• Site-specific labeling |
• Segments must be accessible synthetically |
77, 79, 116 and 118
|
• Multiple probes can be introduced at the same time |
• Difficult to label sites away from the N- or C-terminus |
Also see relevant references for introducing PTMs through NCL and EPL below |
• Access to a wide range of chemical probes |
• Final protein yields may be low |
• May be compatible with isotopic labeling for NMR |
• Not applicable in cells |
• Probes may perturb IDP function and LLPS |
Segmental labeling for NMR spectroscopy |
Cfa GEP |
• Trans-splicing can be achieved under denaturing conditions |
• Splicing reaction must take place at a cysteine residue |
29, 79 and 172
|
• High efficiency |
• Robust to a range of extein sequences |
• May be applied in cells |
MCM2 |
• Salt-inducible splicing can be used to control intein activity |
• Splicing cannot be performed under denaturing conditions |
83
|
• Robust reactivity under high-salt conditions |
• May not be applicable in cells |
• Serine-based reaction mechanism provides versatility |
• Splicing rate and extein sequence compatibility are poor compared to Cfa |
Sortase |
• A possible alternative to intein-based methods |
• Requires the insertion of a five/six amino acid scar into the target protein |
90–96 and 186
|
• May be used to attach proteins to cell surfaces |
• Continued reaction between reactants and desired product may reduce yield |
Introduction of post-translational modifications |
Enzymatic methods |
• Straightforward introduction of native PTMs |
• Lack of control over stoichiometry and location of PTM installation |
100–102
|
Genetic encoding of a bioisostere |
• Straightforward introduction of PTM mimics |
• Scope of PTMs is limited to those that can be mimicked effectively by a bioisostere |
23, 46 and 104
|
• Applicable in cells |
Amber suppression |
• Introduction of native PTMs or PTM mimics |
• Scope of PTMs is limited to those that have a tRNA synthetase available |
105 and 106
|
• Applicable in cells |
• UAA incorporation may be inefficient and lead to low protein yields |
Cysteine alkylation |
• Efficient and specific introduction of methyl-lysine mimics |
• Methyl-lysine mimic may not faithfully reproduce the function of the native PTM |
41, 107, 109 and 110
|
• Reactions are compatible with denaturing conditions |
• Not applicable in cells |
Native chemical ligation and expressed protein ligation |
• Site-specific introduction of PTMs |
• Segments must be accessible synthetically |
125–128, 187 and 188
|
• Multiple PTMs can be introduced at the same time |
• Difficult to introduce PTMs away from the N- or C-terminus |
• Access to a wide range of modifications |
• Final protein yields may be low |
• Not applicable in cells |